{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-039299","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.749715+00:00","generated_at":"2026-05-26T01:32:16.215165+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Soleno reports FY2024 net loss of $175.9M; cash $318.6M; PDUFA for DCCR on March 27, 2025","bullets":["Net loss $(175.9)M ($4.38/share) vs $(39.0)M in 2023; R&D expense $78.6M, G&A $105.9M.","Cash, cash equivalents and marketable securities $318.6M at Dec 31, 2024; used $69.1M in operations.","NDA for DCCR (PWS) under FDA Priority Review with PDUFA target March 27, 2025.","Entered loan agreement with Oxford for up to $200M ($50M upfront); completed $158.7M public offering in May 2024.","Appointed Dawn Carter Bir to Board; Matthew Pauls as Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-039299","json":"https://secwatch.observer/filing/0001193125-25-039299.json","markdown":"https://secwatch.observer/filing/0001193125-25-039299.md","text":"https://secwatch.observer/filing/0001193125-25-039299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525039299/0001193125-25-039299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312525039299/d882131d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:32:16.215165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}